Reference ID: 3416347
Stimulants used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Careful observation for digital changes is necessary during treatment with ADHD stimulants. (5.5) Visual Disturbance: Difficulties with accommodation and blurring of vision have been reported with stimulant treatment. (5.6)
Download Reference ID: 3416347
Information
Domain:
Source:
Link to this page:
Documents from same domain
Effexor (venlafaxine hydrochloride) Tablets …
www.accessdata.fda.govEffexor ® (venlafaxine hydrochloride) Tablets Rx only . Suicidality and Antidepressant Drugs Antidepressants increased the risk compared …
Reference ID: 3101735 - Food and Drug …
www.accessdata.fda.govDocetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
Cytotec® - Food and Drug Administration
www.accessdata.fda.govcytotec® (misoprostol) warnings cytotec (misoprostol) administration to women who are pregnant can cause abortion, premature birth, or birth defects.
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.accessdata.fda.govweakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms . FULL …
Namenda XR (memantine hydrochloride) capsules …
www.accessdata.fda.govThe most commonly observed adverse reactions seen in patients administered NAMENDA XR in the controlled clinical trial, defined as those occurring at a frequency of at least 5% in the
FOR INTRAVENOUS USE ONLY - Food and Drug …
www.accessdata.fda.govNDA 50-706/S-022 Page 3 MERREM® I.V. (meropenem for injection) FOR INTRAVENOUS USE ONLY To reduce the development of drug-resistant bacteria and maintain the effectiveness of
NOT FOR USE IN NEONATES CONTAINS BENZYL …
www.accessdata.fda.govDepo-Medrol® methylprednisolone acetate injectable suspension, USP NOT FOR USE IN NEONATES CONTAINS BENZYL ALCOHOL . Not For Intravenous Use . DESCRIPTION
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.accessdata.fda.govDacogen is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and …
Venofer - Food and Drug Administration
www.accessdata.fda.govNDA 21-135/S-017 Page 3 Venofer ® (iron sucrose injection, USP) Rx Only DESCRIPTION Venofer® (iron sucrose injection, USP) is a brown, sterile, aqueous, complex of …
Diphenhydramine Hydrochloride Injection
www.accessdata.fda.govHOW SUPPLIED Diphenhydramine Hydrochloride Injection, USP is a clear and colorless solution available as: 50 mg/mL in a 1 mL prefilled single-use syringe.
Related documents
Stress Relief - Heat Treat Doctor.com
www.heat-treat-doctor.com“The Heat Treat Doctor”®, President The HERRING GROUP, Inc. P.O. Box 884 Elmhurst, IL 60126-0884 USA www.heat-treat-doctor.com Fig. 1 — Typical stress relief oven for wire coils (photo courtesy of Wisconsin Oven). Table 12. Oven …
An Evidence Based Occupational Therapy Toolkit for ...
professionals.wrha.mb.caclinical decision making as they assess, treat and educate clients recovering from stroke, with the ultimate goal of promoting client self-management. The affected upper extremity has been categorized into low, intermediate or high levels to guide occupational therapists with selecting appropriate assessment tools and treatments.
www.be-ro.co.uk Recipe Inspiration
www.be-ro.co.uk- Basics - Remedies - Recipes A Word on Ingredients SUGAR Caster sugar dissolves easily and is most suitable for cake making, being finer it is more easily creamed than granulated sugar, which is better used in rubbed-in cakes. Demerara and …
Mental Health Facts - NAMI
www.nami.orgMental Health Facts CHILDREN & TEENS Fact: 1 in 5 children ages 13-18 have, or will have a serious mental illness.1 Impact Warning Signs Suicide 20% 11% 10% 8% 20% of youth ages 13-18 live with a mental health condition1 11% of youth have
Circular No.6/2016 Government of India
www.incometaxindia.gov.insecurities, opts to treat them asstock-in-trade,the income arising from transfer of such shares/securities would be treated as its business income, b) In respect of listed shares and securities held for a period of more than 12 months immediately preceding the date of its transfer, if the assessee desires to treat the